Kun for helsepersonell

Søk

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss

Menu

Close

Om ZaviceftaVirkningsmekanismePatogen dekningTidlig hensiktsmessig behandlingIDSA anbefalingØkonomiske holdepunkterSpørsmål og svar om ZAVICEFTAPasientprofilerHAP/VAP pasientcUTI pasientcIAI pasientPediatriske pasienterSpørsmål og svar - FAQsEffekt Real-world evidenceEffektdataSpørsmål og svar om effektSikkerhetSikkerhet hos voksneSikkerhet hos barn/ungdomSpørsmål og svar om sikkerhetDoseringDosering hos voksneDosering hos barn/ungdomSpørsmål og svar om dosering
Antimicrobial resistance is a growing threat, with treatment options urgently needed for patients at risk of MDR Gram-negative infections1,2cUTI pasient Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes.2cUTI patient profile*

Identifying patients with cUTI at high-risk of MDR Gram-negative infections.

Rosa

56-year-old female

Patient history

  • Undergoing chemotherapy following mastectomy for node-positive, left-sided breast cancer
  • Neutropenic (chemotherapy related)
  • Immunosuppressed
  • Recent carbapenem treatment

Symptoms

  • Presented with frequent urination and flank pain
  • Infection symptoms include:
    • Dysuria
    • Fever
    • Disorientated/confused
  • Symptoms ongoing for >36 hours
Diagnosis

cUTI with sepsis

Suspected pathogens

K. pneumoniae, including those resistant to carbapenems (KPC)
Patient risk factors for a MDR 
Gram-negative infection Listen to Gian Maria Rossolini

From the Department of Experimental and Clinical Medicine, University of Florence, Italy as he provides an in-depth introduction to diagnostics and susceptibility testing.

Why ZAVICEFTA is an appropriate choice for your cUTI patients ZAVICEFTA: As effective as best available therapy with Gram-negative cUTI.12Explore moreInfectious Thinking

Listen to episode 6 of our ‘Infectious Thinking’ podcast on critically ill CRE cUTI patients.

LoadingcUTI

Learn more about our cUTI clinical trial efficacy.

LoadingPrescribing information

View ZAVICEFTA prescribing information.

Loading
Footnotes:*The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA (ceftazidime–avibactam) could be considered.
†Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and does not inhibit many class D enzymes.8
§To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.8
The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy.8Abbreviations:COPD, chronic obstructive pulmonary disease; CRE, carbapenem-resistant Enterobacterales; cUTI, complicated urinary tract infection; ESBL, extended spectrum beta-lactamase; HAP, hospital-acquired pneumonia; ICU, intensive care unit; KPC, Klebsiella pneumoniae carbapenemase; MDR, multidrug-resistant; OXA, oxacillinase; VAP, ventilator-associated pneumonia.References:Timsit J-F, et al. Intensive Care Med 2019; 45:573–91.Bonine NG, et al. Am J Med Sci 2019;357:102–10.Bassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65.Miller BM, et al. Am J Infect Control 2016;44:134–7.De Waele J, et al. Intensive Care Med 2018;44:189–96.Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23.Harris AD, et al. Emerg Infect Dis 2007;13:1144–9.ZAVICEFTA. Summary of Product Characteristics, 2022.Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71.Zhanel GG, et al. Drugs 2013;73:159–77.Mazuski JE, et al. Surg Infect 2017;18:1–76.Carmeli Y, et al. Lancet Infect Dis 2016;16:661–73.Torres A, et al. Lancet Infect Dis 2018;18:285–95.Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9.Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62.
Preparatomtale
PP-ZVA-NOR-0141 Mai 2023
Pasientprofiler

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei